Signum Biosciences wins $1.6 million Phase II grant from NIAID

Signum Biosciences, a biotechnology company, has received a $1.6 million Small Business Innovation Research Phase II grant from the National Institute of Allergy and Infection Diseases or NIAID to continue the development of its topical signal transduction modulator anti-inflammatory technology for the treatment of inflammatory skin disease.

In 2008, NIH/NIAID awarded Signum a Small Business Innovation Research (SBIR) Phase I grant to establish this novel class of anti-inflammatories. SBIR Phase II grants enable SBIR Phase I grantees to further develop their technology and prepare it for commercialization

Signum will use the Phase II grant to fund preclinical development of Signum's lead drug candidates for rosacea. The objective of the Phase II grant is to be granted an investigational new drug and commence Phase I clinical trials.

Maxwell Stock, president and COO of Signum, said: "We are proud to have been awarded this grant and to have the reviewers at the National Institutes of Health (NIH) validate our technology. Building on our Phase I achievements, Signum is dedicated to developing its signal transduction modulator anti-inflammatory platform as novel therapeutics for rosacea as well as several other dermal skin disorders."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: biotechnology, clinical, grants, health, infection, research, small business, technology